Advertisement

Medical Oncology

, Volume 27, Issue 2, pp 177–184 | Cite as

Glucose metabolism disorders in cancer patients in a Chinese population

  • Ya-Shi ZhanEmail author
  • Lie FengEmail author
  • Shao-Hui Tang
  • Wan-Geng Li
  • Meng Xu
  • Tian-Fu Liu
  • You-Fen Zhou
  • Yu-Lin Ma
  • Yun Zhang
  • Xian-Ming Pu
Original Paper

Abstract

Background Characteristics of glucose metabolism disorders (GMDs) in different cancers and the contributory role of GMDs in developing cancers are still not so clear. Methods Two thousand four hundred and five patients with malignancy who had been hospitalized in the First Affiliated Hospital of Jinan University were pooled as case group. Two thousand and sixteen non-cancer people who finished health examinations in the Affiliated Yangcheng Hospital of Guangzhou Medical College were enrolled as control group. We compared glucose metabolism among patients with different kinds of malignancy. Based on logistic regression models, we analyzed factors that affect the development of carcinoma. Results (1) Among 2,408 malignancy patients, the total prevalence of diabetes mellitus (DM) and impaired fasting glucose (IFG) reached 28.0%. Pancreatic cancer, lymphoma, liver cancer, leukemia, and colorectal cancer showed most striking hyperglycemia. (2) Leukemia and esophageal cancer accounting for 12.5% and 12.1%, respectively, were the most likely to suffer from hypoglycemia. (3) Older cancer patients seem to be more vulnerable to hyperglycemia, while the younger tend to be more likely to develop hypoglycemia. (4) High level of fasting plasma glucose (FPG) was associated with lung cancer, breast cancer, leukemia, lymphoma, thyroid cancer, bladder cancer, and pancreatic cancer. Patients with DM increased risks for developing colorectal cancer, liver cancer, esophageal cancer, thyroid cancer, cervical cancer, and pancreatic cancer. Conclusions GMDs are frequent events in malignancy patients. Hyperglycemia and hypoglycemia are found in the same kinds or different kinds of cancers, and the incidence of hyperglycemia is higher than that of hypoglycemia. Characteristics of GMDs were dissimilar in different cancers and different ages. Hyperglycemia was a risk factor for many cancers.

Keywords

Cancer Glucose metabolism Diabetes mellitus Impaired fasting glucose Hyperglycemia Hypoglycemia 

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50. doi: 10.1200/JCO.2005.05.2308.CrossRefPubMedGoogle Scholar
  2. 2.
    Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst. 1993;85(11):862–74. doi: 10.1093/jnci/85.11.862.CrossRefPubMedGoogle Scholar
  3. 3.
    Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier AM, et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer. 2008;44(1):115–22. doi: 10.1016/j.ejca.2007.10.022.CrossRefPubMedGoogle Scholar
  4. 4.
    World Health Organization. Diabetes mellitus. Geneva, Switzerland: World Health Organization; 2002. p. 138. WHO Fact Sheet.Google Scholar
  5. 5.
    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53. doi: 10.2337/diacare.27.5.1047.CrossRefPubMedGoogle Scholar
  6. 6.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533–9. doi: 10.1136/gut.2004.052167.CrossRefPubMedGoogle Scholar
  7. 7.
    Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166(17):1871–7. doi: 10.1001/archinte.166.17.1871.CrossRefPubMedGoogle Scholar
  8. 8.
    Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819–23. doi: 10.1007/s00125-006-0468-0.CrossRefPubMedGoogle Scholar
  9. 9.
    Washio M, Mori M, Khan M, Sakauchi F, Watanabe Y, Ozasa K, et al. Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). Int J Urol. 2007;14(5):393–7. doi: 10.1111/j.1442-2042.2007.01744.x.CrossRefPubMedGoogle Scholar
  10. 10.
    Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care. 2003;26(6):1752–8. doi: 10.2337/diacare.26.6.1752.CrossRefPubMedGoogle Scholar
  11. 11.
    Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol. 2008;167(5):607–14. doi: 10.1093/aje/kwm333.CrossRefPubMedGoogle Scholar
  12. 12.
    Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007;16(1):83–9. doi: 10.1097/01.cej.0000228404.37858.40.CrossRefPubMedGoogle Scholar
  13. 13.
    Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):921–9. doi: 10.1158/1055-9965.EPI-07-2686.CrossRefPubMedGoogle Scholar
  14. 14.
    Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology. 2005;129(2):464–75.PubMedGoogle Scholar
  15. 15.
    Bermont L, Lamielle F, Lorchel F, Fauconnet S, Esumi H, Weisz A, et al. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab. 2001;86(1):363–8. doi: 10.1210/jc.86.1.363.CrossRefPubMedGoogle Scholar
  16. 16.
    Yakar S, Pennisi P, Zhao H, Zhang Y, LeRoith D. Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse. Novartis Found Symp. 2004;262:3–9; discussion 9–18, 265–8.Google Scholar
  17. 17.
    Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer. 2006;13(2):273–8. doi: 10.1677/erc.1.01219.CrossRefPubMedGoogle Scholar
  18. 18.
    Aleksandrovski YA. Molecular mechanisms of the cross-impact of pathological processes in combined diabetes and cancer. Research and clinical aspects. Biochemistry (Mosc). 2002;67(12):1329–46. doi: 10.1023/A:1021801808405.CrossRefGoogle Scholar
  19. 19.
    Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev. 2004;13(6):915–9.PubMedGoogle Scholar
  20. 20.
    Ely JT, Krone CA. Glucose and cancer. N Z Med J. 2002;115(1159):U123.PubMedGoogle Scholar
  21. 21.
    Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med. 2007;5:17. doi: 10.1186/1741-7015-5-17.CrossRefPubMedGoogle Scholar
  22. 22.
    Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044–50. doi: 10.1053/j.gastro.2004.07.011.CrossRefPubMedGoogle Scholar
  23. 23.
    Nan DN, Fernandez-Ayala M, Vega Villegas ME, Garcia-Castano A, Rivera F, Lopez-Brea M, et al. Diabetes mellitus following cisplatin treatment. Acta Oncol. 2003;42(1):75–8. doi: 10.1080/0891060310002276.CrossRefPubMedGoogle Scholar
  24. 24.
    Galassetti P, Tate D, Neill RA, Richardson A, Leu SY, Davis SN. Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab. 2006;290(6):E1109–17. doi: 10.1152/ajpendo.00244.2005.CrossRefPubMedGoogle Scholar
  25. 25.
    Venkatraman R, Jayashree M, Singhi S, Marwaha RK. Hyperglycemic hyperosmolar nonketotic syndrome in a child with acute lymphoblastic leukemia undergoing induction chemotherapy: case report. J Pediatr Hematol Oncol. 2005;27(4):234–5. doi: 10.1097/01.mph.0000161530.40065.2f.CrossRefPubMedGoogle Scholar
  26. 26.
    Chala E, Manes C, Iliades H, Skaragkas G, Mouratidou D, Kapantais E. Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy. Hormones (Athens). 2006;5(2):137–46.Google Scholar
  27. 27.
    Tanaka H, Kobayashi A, Bando M, Hosono T, Tsujita A, Yamasawa H, et al. Case of small cell lung cancer complicated with diabetes insipidus and Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. Nihon Kokyuki Gakkai Zasshi. 2007;45(10):793–8.PubMedGoogle Scholar
  28. 28.
    Agha A, Brennan S, Moore KB, Grogan L, Thompson CJ. Small-cell lung cancer presenting as diabetes insipidus and Cushing’s syndrome. Pituitary. 2005;8(2):105–7. doi: 10.1007/s11102-005-3308-1.CrossRefPubMedGoogle Scholar
  29. 29.
    Pfeffer F, Koczan D, Adam U, Benz S, von Dobschuetz E, Prall F, et al. Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas. 2004;29(4):284–90. doi: 10.1097/00006676-200411000-00007.CrossRefPubMedGoogle Scholar
  30. 30.
    Liu H, Xia Y, Cui N. Impact of diabetes mellitus on treatment outcomes in patients with nasopharyngeal cancer. Med Oncol. 2006;23(3):341–6. doi: 10.1385/MO:23:3:341.CrossRefPubMedGoogle Scholar
  31. 31.
    Ujpal M, Barabas J, Szabo G, Bogdan S, Lorincz A, Suba Z. Prognostic significance of type 2 diabetes in patients treated with surgery and irradiation for gingival cancer. Fogorv Sz. 2007;100(3):99–102.PubMedGoogle Scholar
  32. 32.
    Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer. 2007;17(2):441–6. doi: 10.1111/j.1525-1438.2007.00790.x.CrossRefPubMedGoogle Scholar
  33. 33.
    Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101. doi: 10.1053/j.gastro.2007.10.040.CrossRefPubMedGoogle Scholar
  34. 34.
    Geetha N, Lali VS, Hussain BM, Nair MK. Insulin dependent diabetes mellitus induced by chemotherapy and granulocyte, macrophage-colony stimulating factor. J Assoc Physicians India. 1999;47(8):835.PubMedGoogle Scholar
  35. 35.
    Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25(22):1990–7. doi: 10.1016/j.ehj.2004.09.021.CrossRefPubMedGoogle Scholar
  36. 36.
    Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst. 2006;98(2):135–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Ehrmann-Josko A, Sieminska J, Gornicka B, Ziarkiewicz-Wroblewska B, Ziolkowski B, Muszynski J. Impaired glucose metabolism in colorectal cancer. Scand J Gastroenterol. 2006;41(9):1079–86. doi: 10.1080/00365520600587444.CrossRefPubMedGoogle Scholar
  38. 38.
    Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2007;18(5):493–503. doi: 10.1007/s10552-007-0126-y.CrossRefPubMedGoogle Scholar
  39. 39.
    Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, et al. Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study. Breast Cancer Res Treat. 2008;108(1):129–35. doi: 10.1007/s10549-007-9585-9.CrossRefPubMedGoogle Scholar
  40. 40.
    Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28(3):590–4. doi: 10.2337/diacare.28.3.590.CrossRefPubMedGoogle Scholar
  41. 41.
    Sun G, Vasdev S, Martin GR, Gadag V, Zhang H. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005;54(11):3336–9. doi: 10.2337/diabetes.54.11.3336.CrossRefPubMedGoogle Scholar
  42. 42.
    Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1458–63. doi: 10.1158/1055-9965.EPI-06-0188.CrossRefPubMedGoogle Scholar
  43. 43.
    Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008;109(2):389–95. doi: 10.1007/s10549-007-9654-0.CrossRefPubMedGoogle Scholar
  44. 44.
    Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC. Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis. 2007;28(7):1561–6. doi: 10.1093/carcin/bgm081.CrossRefPubMedGoogle Scholar
  45. 45.
    Haidar A, Yassin A, Saad F, Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10(4):189–96. doi: 10.1080/13685530701653538.CrossRefPubMedGoogle Scholar
  46. 46.
    Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70(6):1104–8. doi: 10.1016/j.urology.2007.08.012.CrossRefPubMedGoogle Scholar
  47. 47.
    Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100(5):1060–5.PubMedGoogle Scholar
  48. 48.
    Meyer P, Zuern C, Hermanns N, Haak T. The association between paternal prostate cancer and type 2 diabetes. J Carcinog. 2007;6:14. doi: 10.1186/1477-3163-6-14.CrossRefPubMedGoogle Scholar
  49. 49.
    Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056–62. doi: 10.1158/1055-9965.EPI-06-0410.CrossRefPubMedGoogle Scholar
  50. 50.
    Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21(3):433–40. doi: 10.1200/JCO.2003.07.125.CrossRefPubMedGoogle Scholar
  51. 51.
    Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87.PubMedGoogle Scholar
  52. 52.
    Assaad SN, Vassilopoulou-Sellin R, Samaan NA. Pseudohypoglycemia in chronic leukemia. Tex Med. 1988;84(7):36–7.PubMedGoogle Scholar
  53. 53.
    Holroyde CP, Skutches CL, Boden G, Reichard GA. Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res. 1984;44(12 Pt 1):5910–3.PubMedGoogle Scholar
  54. 54.
    Lattermann R, Geisser W, Georgieff M, Wachter U, Goertz A, Gnann R, et al. Integrated analysis of glucose, lipid, and urea metabolism in patients with bladder cancer. Impact of tumor stage. Nutrition. 2003;19(7–8):589–92. doi: 10.1016/S0899-9007(03)00055-8.CrossRefPubMedGoogle Scholar
  55. 55.
    Richards EW, Long CL, Nelson KM, Pinkston JA, Navari RM, Geiger JW, et al. Glucose metabolism in advanced lung cancer patients. Nutrition. 1992;8(4):245–51.PubMedGoogle Scholar
  56. 56.
    Shiba T, Higashi N, Nishimura Y. Hyperglycemia due to insulin resistance caused by interferon-gamma. Diabet Med. 1998;15(5):435–6. doi: 10.1002/(SICI)1096-9136(199805)15:5<435::AID-DIA566>3.0.CO;2-N.CrossRefPubMedGoogle Scholar
  57. 57.
    Heber D, Chlebowski RT, Ishibashi DE, Herrold JN, Block JB. Abnormalities in glucose and protein metabolism in noncachectic lung cancer patients. Cancer Res. 1982;42(11):4815–9.PubMedGoogle Scholar
  58. 58.
    Matsuyama T, Tanaka R, Shima K, Nonaka K, Tarui S. Lack of gastrointestinal glucagon response to hypoglycemia in depancreatized dogs. Diabetologia. 1978;15(6):471–4. doi: 10.1007/BF02342872.CrossRefPubMedGoogle Scholar
  59. 59.
    Diaz R, Aparicio J, Mendizabal A, Faus M, Fleitas T, Aparisi F, et al. Paraneoplastic hyperinsulinism and secondary hypoglycemia in a patient with advanced colon cancer: a rare association. World J Gastroenterol. 2008;14(12):1952–4. doi: 10.3748/wjg.14.1952.CrossRefPubMedGoogle Scholar
  60. 60.
    Bessell EM, Selby C, Ellis IO. Severe hypoglycemia caused by raised insulin-like growth factor II in disseminated breast cancer. J Clin Pathol. 1999;52(10):780–1. doi: 10.1136/jcp.52.10.780.CrossRefPubMedGoogle Scholar
  61. 61.
    Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2006;118(8):2105–9. doi: 10.1002/ijc.21600.CrossRefPubMedGoogle Scholar
  62. 62.
    Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160–7. doi: 10.1093/aje/kwh161.CrossRefPubMedGoogle Scholar
  63. 63.
    Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control. 2004;15(9):873–81. doi: 10.1007/s10552-004-1050-z.CrossRefPubMedGoogle Scholar
  64. 64.
    Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194–202. doi: 10.1001/jama.293.2.194.CrossRefPubMedGoogle Scholar
  65. 65.
    Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62(4):1030–5.PubMedGoogle Scholar
  66. 66.
    Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6(2):103–11. doi: 10.1016/S1470-2045(05)01736-5.CrossRefPubMedGoogle Scholar
  67. 67.
    Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol. 2003;163(3):1001–11.PubMedGoogle Scholar
  68. 68.
    Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care. 2006;29(8):1990–1. doi: 10.2337/dc06-0997.CrossRefPubMedGoogle Scholar
  69. 69.
    Reinmuth N, Fan F, Liu W. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 2002;82(10):1377–89.PubMedGoogle Scholar
  70. 70.
    Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74. doi: 10.1007/s00125-007-0681-5.CrossRefPubMedGoogle Scholar
  71. 71.
    Huxley R. The role of lifestyle risk factors on mortality from colorectal cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007;8(2):191–8.PubMedGoogle Scholar
  72. 72.
    Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166(8):932–40. doi: 10.1093/aje/kwm170.CrossRefPubMedGoogle Scholar
  73. 73.
    Huxley R. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007;8(2):199–205.PubMedGoogle Scholar
  74. 74.
    Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571–8. doi: 10.1002/ijc.22788.CrossRefPubMedGoogle Scholar
  75. 75.
    Kruk J. Association of lifestyle and other risk factors with breast cancer according to menopausal status: A case-control study in the region of WesternPomerania (Poland). Asian Pac J Cancer Prev. 2007;8(4):513–24.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Ya-Shi Zhan
    • 1
    • 2
    Email author
  • Lie Feng
    • 1
    Email author
  • Shao-Hui Tang
    • 1
  • Wan-Geng Li
    • 3
  • Meng Xu
    • 1
  • Tian-Fu Liu
    • 4
  • You-Fen Zhou
    • 1
  • Yu-Lin Ma
    • 2
  • Yun Zhang
    • 5
  • Xian-Ming Pu
    • 2
  1. 1.Department of EndocrinologyThe First Affiliated Hospital, Jinan UniversityGuangzhouChina
  2. 2.Department of EndocrinologyAffiliated Xiaolan Hospital, Southern Medical UniversityZhongshanChina
  3. 3.Department of Endocrinology the second Affiliated HospitalGuangzhou Medical collegeGuangzhouChina
  4. 4.Department of Internal MedicineGuangzhou Integrated Traditional and Western HospitalGuangzhouChina
  5. 5.Department of Internal MedicineAffiliated Yangcheng Hospital, Guangzhou Medical CollegeGuangzhouChina

Personalised recommendations